Page 11 - John Oyler News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from John oyler. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In John Oyler Today - Breaking & Trending Today

These 10 Colleges Have Produced The Most Billionaire Alumni


These 10 Colleges Have Produced The Most Billionaire Alumni
Tristar Media/Getty Images, Prodip Guha/Getty Images, Danny Moloshok/REUTERS/Newscom
American universities dominate, but it’s not all Ivy Leaguers on the 2021 World’s Billionaires list.
The 2,755 people on
Forbes’ 2021 World’s Billionaires list received their undergraduate degrees all over the world, from Al-Azhar University in Egypt to the Zhejiang University of Technology in China. Hundreds did not attend college at all, or left before obtaining a diploma, including a pair of Harvard dropouts who are among the five richest people in the world: Bill Gates and Mark Zuckerberg.
But among the billionaires who completed their undergraduate education, a few schools stand out. Harvard leads the way, with at least 29 billionaire alumni on the ....

United States , Wharton School , Stanford University , Yale University , Harvard Yard , Soult Ukpyolsi , South Korea , Massachusetts Institute Of Technology , Harvard University , University Of Southern California , University Of Pennsylvania , New Haven , United Kingdom , Los Angeles , B Wayne Hughes Jr , Michael Saylor , Premchand Godha , Goldman Sachs , Mark Zuckerberg , Jerry Yang , Mackenzie Scott , Lance Gokongwei , Lloyd Blankfein , Baiju Bhatt , Steve Ballmer , Edward Bass ,

Fierce Pharma Asia—BeiGene-Novartis PD-1 deal; Sinovac vaccine; Celltrion antibody COVID-19 data


Brazilian researchers first said Sinovac’s COVID-19 vaccine, CoronaVac, was 78% effective in a local phase 3 trial. But then, a few days ago, they released new data of just 50.4% efficacy. The gap was caused by the omission of “very mild” infections in the previous data. The misstep led to criticism of the trial organization, Brazil’s Butantan biomedical center, as well as suspicion about CoronaVac’s true efficacy. Turkey just authorized the shot for emergency use based on a reported 91.25% efficacy in an interim analysis of its local trial.
Celltrion’s anti-coronavirus antibody helped patients with mild-to-moderate COVID-19 in a phase 2/3 clinical trial. Top-line data from 327 subjects showed CT-P59 cut the risk of progression to severe disease by 54%, shortened time to clinical recovery and reduced viral load. The Korean company has filed for conditional marketing authorization in its home country and aims for U.S. and European go-aheads in the coming months. ....

United States , Michael Goettler , John Oyler , Sinovac Biotech , South Korea , Pd 1 L1 , Covid 19 , Vaccine Development , Antibody Drugs , ஒன்றுபட்டது மாநிலங்களில் , ஜான் ஓயிளெர் , தெற்கு கொரியா , பி.டி. எல்1 , தடுப்பூசி வளர்ச்சி , ஆன்டிபாடி மருந்துகள் ,